Lumryz

News

Alkermes offers more for Avadel after Lundbeck bid

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Alkermes bets $2.1bn on Avadel and its narcolepsy drug

Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

News

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks